Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
Csizmarik A, Nagy N, Keresztes D, Váradi M, Bracht T, Sitek B, Witzke K, Puhr M, Tornyi I, Lázár J, Takács L, Kramer G, Sevcenco S, Maj-Hes A, Hadaschik B, Nyirády P, Szarvas T. Csizmarik A, et al. Among authors: keresztes d. Prostate Cancer Prostatic Dis. 2024 Sep;27(3):451-456. doi: 10.1038/s41391-023-00713-y. Epub 2023 Aug 26. Prostate Cancer Prostatic Dis. 2024. PMID: 37634036 Free PMC article.
Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
Varadi M, Nagy N, Reis H, Hadaschik B, Niedworok C, Modos O, Szendroi A, Ablat J, Black PC, Keresztes D, Csizmarik A, Olah C, Gaisa NT, Kiss A, Timar J, Toth E, Csernak E, Gerstner A, Mittal V, Karkampouna S, Kruithof de Julio M, Gyorffy B, Bedics G, Rink M, Fisch M, Nyirady P, Szarvas T. Varadi M, et al. Among authors: keresztes d. Cancer Med. 2023 Apr;12(7):9041-9054. doi: 10.1002/cam4.5639. Epub 2023 Jan 20. Cancer Med. 2023. PMID: 36670542 Free PMC article.
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Csizmarik A, Keresztes D, Nagy N, Bracht T, Sitek B, Witzke K, Puhr M, Tornyi I, Lázár J, Takács L, Kramer G, Sevcenco S, Maj-Hes A, Jurányi Z, Hadaschik B, Nyirády P, Szarvas T. Csizmarik A, et al. Among authors: keresztes d. Int J Cancer. 2022 Oct 15;151(8):1405-1419. doi: 10.1002/ijc.34159. Epub 2022 Jun 21. Int J Cancer. 2022. PMID: 35689436 Free PMC article.
Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer.
Keresztes D, Csizmarik A, Nagy N, Módos O, Fazekas T, Bracht T, Sitek B, Witzke K, Puhr M, Sevcenco S, Kramer G, Shariat S, Küronya Z, Takács L, Tornyi I, Lázár J, Hadaschik B, Lászik A, Szűcs M, Nyirády P, Szarvas T. Keresztes D, et al. J Cell Mol Med. 2022 Feb;26(4):1332-1337. doi: 10.1111/jcmm.17141. Epub 2021 Dec 30. J Cell Mol Med. 2022. PMID: 34970839 Free PMC article.
Prevalence of APC and PTEN Alterations in Urachal Cancer.
Nagy N, Reis H, Hadaschik B, Niedworok C, Módos O, Szendrői A, Bíró K, Hager T, Herold T, Ablat J, Black PC, Okon K, Tolkach Y, Csizmarik A, Oláh C, Keresztes D, Bremmer F, Gaisa NT, Kriegsmann J, Kovalszky I, Kiss A, Tímár J, Szász MA, Rink M, Fisch M, Nyirády P, Szarvas T. Nagy N, et al. Among authors: keresztes d. Pathol Oncol Res. 2020 Oct;26(4):2773-2781. doi: 10.1007/s12253-020-00872-6. Epub 2020 Aug 4. Pathol Oncol Res. 2020. PMID: 32754865 Free PMC article.
15 results